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Most patients with pancreatic cancer present with advanced disease and die within the first year
after diagnosis. Predictive biomarkers that signal the presence of pancreatic cancer in an early stage
are desperately needed. We aimed to identify new and validate previously found plasma
metabolomic biomarkers associated with early stages of pancreatic cancer. Prediagnostic blood
samples from individuals who were to receive a diagnosis of pancreatic cancer between 1 month
and 17 years after sampling (N 5 356) and age- and sex-matched controls (N 5 887) were collected
from five large population cohorts (HUNT2, HUNT3, FINRISK, Estonian Biobank, Rotterdam Study).
We applied proton nuclear magnetic resonance–based metabolomics on the Nightingale platform.
Logistic regression identified two interesting hits: glutamine (P 5 0.011) and histidine (P 5 0.012),
with Westfall–Young family-wise error rate adjusted P values of 0.43 for both. Stratification in
quintiles showed a 1.5-fold elevated risk for the lowest 20% of glutamine and a 2.2-fold increased
risk for the lowest 20% of histidine. Stratification by time to diagnosis suggested glutamine to be
involved in an earlier process (2 to 5 years before diagnosis), and histidine in a process closer to the
actual onset (,2 years). Our data did not support the branched-chain amino acids identified earlier
in several US cohorts as potential biomarkers for pancreatic cancer. Thus, although we identified
glutamine and histidine as potential biomarkers of biological interest, our results imply that a study
at this scale does not yield metabolomic biomarkers with sufficient predictive value to be clinically
useful per se as prognostic biomarkers. (Endocrinology 160: 1731–1742, 2019)
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Pancreatic cancer is one of the most lethal cancersworldwide and is increasingly common (1–3). Most
patients present with advanced and thus incurable dis-
ease and die within a year of the initial diagnosis (3, 4).
There is an imminent need to identify these patients
earlier in the disease process, as patients with resectable,
nonmetastatic cancer can potentially be cured. For many
cancers it takes several years for a local malignant lesion
to progress to fully metastasized disease, and pancreatic
cancer is no exception (5). Thus, there should be a
window of opportunity for timely detection and in-
tervention. Unfortunately, for early, presymptomatic
pancreatic cancer currently no specific biomarkers are
available. The identification of predictive biomarkers is
complicated by the low incidence rate of the disease,
estimated at 7 to 12 cases per 100,000 adult person years
in the Western European population (6, 7).
It is well known that the development and progression
of pancreatic cancer are associated with alterations in
systemic metabolism. Patients may present with glucose
intolerance, anorexia, and severe weight loss (3, 8). In
line with this, circulating metabolites have been proposed
as a potentially useful screening tool in pancreatic cancer
(9–16). The study by Mayers et al. (11) stood out from
other metabolomic biomarker studies, as they analyzed
blood samples taken 2 to more .10 years prior to di-
agnosis. They found an elevation of circulating branched-
chain amino acids as an early event in the development of
pancreatic cancer (11).
Considering these metabolomics biomarkers as
promising, we set out to replicate these findings in-
dependently in five large European population cohorts
and find additional biomarkers associated with early
stages of pancreatic cancer, using a different platform,
proton nuclear magnetic resonance (1H-NMR) in-
stead of liquid chromatography followed by mass
spectrometry. This is a retrospective study where
biobanked samples from population cohorts were
cross-checked with the national cancer registries to
identify samples from individuals who were diagnosed
with pancreatic cancer after blood sampling. This was
done because truly prospective studies are almost
infeasible with low-incident diseases such as pancre-
atic cancer.
Methods
Study population
Our study population consisted of pancreatic cancer
cases and controls, drawn from five national European co-
horts, collaborating in the Biobanking and Biomolecular
Resources Research Infrastructure Large Population Co-
horts (BBMRI-LPC; www.bbmri-lpc-biobanks.eu) and the
cross-infrastructure project CORBEL (www.corbel-project.eu):
the Estonian Genome Center of the University of Tartu study
(EGCUT), the FINRISK Study (FR), the Nord-Trøndelag
Health Study (HUNT2 and HUNT3), and the Rotterdam
Study (RS).
EGCUT is a volunteer-based sample of the Estonian resident
adult population aged$18 years, started in 1999, and currently
has nearly 152,000 participants (17). EGCUT can link its own
database with the national electronic databases (eight total) to
constantly update the phenotype information for the subjects.
Every entry in the biobank consists of: (i) biological samples,
(ii) answers to the questions of a computer-assisted personal
interview conducted at the doctor’s office, (iii) objective
measurements performed at the doctor’s office, (iv) electronic
health data from various databases, (v) genotype data from
array genotyping, exome sequencing, or whole-genome se-
quencing, and (vi) biomedical data obtained by performing
various assays on the material collected.
FINRISK was initiated in 1972 and includes a collection of
cross-sectional surveys in the adult (25- to 74-year-old) per-
manent residents of selected geographical areas of Finland.
Altogether, FINRISK had nine cross-sectional surveys per-
formed every fifth year by the National Institute for Health and
Welfare, including a total of 101,451 invitees (18). Participants
in this study were selected from the FINRISK 1997, 2002, and
2007 surveys. There are no reexaminations except for occa-
sional people who were selected to more than one independent
survey by chance. Follow-up is carried out through record
linkages to national administrative registers (such as the Causes
of Death Register and Cancer Register) by using a unique
personal identity code (19).
HUNT includes repeated surveys of a large population-
based cohort in Norway. Data from 116,044 individuals
aged$20 years from HUNT2 (1995 to 1997, n5 65,237) and
HUNT3 (2006 to 2008, n 5 50,807) were used in this study.
Individuals who participated in both HUNT2 and HUNT3
were only included in the current study as part of HUNT3.
Similar to FINRISK, follow-up is carried out through record
linkages to national administrative registers (such as the Causes
of Death Register and Cancer Register) by using a unique
personal identity code (20).
The RS is an ongoing, population-based cohort study
in a suburban area of Rotterdam, Netherlands. At baseline,
all participants underwent both an interview at home and an
extensive set of examinations at a research facility, and blood
samples (both plasma and serum) were collected. At each
follow-up point, blood samples were collected. It was ini-
tiated in 1989 and has enrolled 14,926 individuals of $45
years of age since then. Follow-up is carried out every three to
four years. An automated follow-up system is linked to
digital medical records from general practitioners (including
discharge letters from hospitals) and linked to a registry of
histopathology and cytopathology [Pathologisch-Anatomisch
Landelijk Geautomatiseerd Archief (PALGA)] and to Landelijke
Medische Registratie (LMR) and the Integraal Kankercentrum
Nederland (IKNL) (21, 22).
All participants of the respective cohorts provided written
informed consent. The current study was approved by the local
ethics committee of each study.
Selection of cases and controls
We included incident pancreatic cancer cases, confirmed by
pathology and diagnosed after blood collection. Cases were
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identified through national cancer registries and through in-
dependent review of medical records. For diagnosis of pan-
creatic cancer, we used the ICD-10 C25.0 code. Deaths were
ascertained through the national registries. We excluded cases
that lived .5 years after diagnosis to avoid false-positive di-
agnoses (23–25).
For each case, we selected two (in RS one, in EGCUT four)
random controls, matching on cohort, sex, age at sample
collection (62 years), and time of blood collection. Controls
were those who were alive and without a diagnosis of pan-
creatic cancer at time of the case’s diagnosis date.
Ascertainment of other covariates
The following covariate data were obtained from ques-
tionnaires and physical examination before blood collection:
body mass index (BMI; kg/m2), smoking status (current/former/
never), type 2 diabetes mellitus (T2DM) status, and fasting
status (,4 hours/4 to 8 hours/.8 hours).
Metabolite profiling and quality control
Serum was collected from serum separator tubes with glass
or silica clot activators, with or without gel as separator, and
stored at280°C. EDTA plasma was collected from Vacutainer
tubes and processed and stored at 280°C within 48 hours of
blood draw. Metabolites were quantified from EDTA plasma
(EGCUT) or serum (HUNT2, HUNT3, FR, RS) samples using a
high-throughput 1H-NMR metabolomics platform (Nightin-
gale Health, Helsinki, Finland; https://nightingalehealth.com/).
This platform provides simultaneous quantification of 147
individual metabolites and 79 metabolite ratios, for exam-
ple, routine lipids, lipoprotein subclass profiling with lipid
concentrations within 14 subclasses, esterified fatty acid
composition, and various low-molecular-weight metabolites,
including amino acids, ketone bodies, and gluconeogenesis-
related metabolites in molar concentration units. Details of
the experimentation and applications of the platform have
been described previously (26).
Metabolite measures that failed quality control (in par-
ticular for glutamine, pyruvate, glycerol, hydroxybutyrate,
and acetate) were excluded from the analysis on a per-individual
basis. One metabolite measure (glycerol) with .10% miss-
ing values was excluded entirely, resulting in a final number
of 146 metabolite measures and 79 ratios. Outliers (.5 SD)
were removed in concordance with previous research in this
field (27).
Statistical analysis
Differences in baseline characteristics between cases and
controls were assessed for each cohort separately using two-
tailed Student t tests (continuous variables) or x2 tests (cate-
gorical variables).
Metabolite measurements were raised by 1 to allow log
transformation. Thereafter, all metabolite values were log-
transformed and scaled to obtain unit SD for each cohort.
They were included as continuous variables in logistic regression
models and adjusted for matching factors (sex and age at sample
collection, minimally adjusted model). In our main model on the
pooled data from all of the cohorts, we additionally adjusted for
BMI, smoking status, T2DM status, fasting status, and cohort. P
values were corrected for multiple testing using Westfall and
Young family-wise error rate, an appropriate method given the
strong correlations between the measurements of the different
metabolites (28). To provide estimates of effect magnitude,
significant metabolites were again examined in logistic regression
models after categorization in quintiles. Quintiles were generated
based on the metabolite values in controls only. Results are
presented as ORs and 95% CIs.
Figure 1. Schematic overview of the sample set used for data analysis and the different data analysis approaches performed in the current
study. aAny individual containing missing values in metabolomics measurements or phenotypical information were assumed to be missing at
random and were removed from the data set. bAny individual containing missing values in phenotypical information were removed from the
data set. PC, pancreatic cancer.
doi: 10.1210/en.2019-00165 https://academic.oup.com/endo 1733
D
ow
nloaded from
 https://academ
ic.oup.com
/endo/article-abstract/160/7/1731/5497119 by Erasm
us U
niversiteit R
otterdam
 user on 21 August 2019
As an alternative for the pooling of the data from the different
cohorts, we also performed a logistic regression per cohort (with
sex, age, BMI, smoking status, T2DM, and fasting status as
covariates) and a subsequent meta-analysis. The obtained esti-
mates for the metabolite measures and their standard errors were
used in a random effects meta-analysis using the R package meta
4.9.2 (29). A random effects model was chosen to account for
possible heterogeneity due to differences in disease assessment,
sample processing, and sample collection between cohorts.
Heterogeneity was assessed using the I2 statistic and by visual
inspection of forest plots. P values from the meta-analysis
were corrected for multiple-testing using a Bonferroni–Holm
test.
LASSO regression to evaluate additive effect of
metabolomics biomarkers on top of
clinical predictors
To select biomarkers with predictive value, we applied a
fivefold cross-validated penalized least absolute shrinkage and
selection operator (LASSO) regression with the penalized
package version 0.9-51 (30). The clinical covariates (sex, age,
BMI, smoking status, T2DM status, fasting status, and cohort)
were not penalized and thus were always present in the model.
We performed a stratified analysis, including all controls but
only cases who developed pancreatic cancer within 2 years or
within 5 years after blood sampling or including all cases. For
the variable selection, the data were split randomly into a data
set for variable selection (70% of the data, with 35% for
training and 35% for cross-validation) and a data set for
performance testing (30% of the data). We compared the
performance of the null model (with only the clinical covariates)
with the model that included the selected metabolites using an
ordinary least squares regression model. The performance of
the different model was assessed by evaluating the area under
the receiver operator curve (AUC).
General
Analyses were performed using the software packages meta
4.9-2, Penalized 0.9-51, Globaltest 5.24.0, InformationValue
1.2.3, ROCR 1.0-7, RColorBrewer 1.1-2, and ggplot2 3.0.0 for
R version 3.2.3. All scripts are available in an online re-
pository (31).
Availability of data
Additional files with complete results are available in an
online repository (32). For reasons of privacy protection, raw
data are only available upon request.
Results
Study population and measurements
Cross-checking of the individuals in the five pop-
ulation cohorts included in this study with the na-
tional cancer registries enabled us to identify 444
prediagnostic samples from subjects who received
diagnosis of pancreatic cancer between 1 month and
17 years after blood sampling (median, 4.68 years).
We subsequently selected 1012 sex- and age-matched
controls from the same cohorts (Fig. 1). Baseline Ta
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characteristics for all cohorts are shown in Table 1.
Baseline characteristics differed significantly between
cohorts (in particular for sex, BMI, T2DM, and fasting
status). Cases were significantly and consistently
enriched for T2DM patients and smokers, in line with
the comorbidity of pancreatic cancer and T2DM
and smoking as a known risk factors for pancreatic
cancer (Table 1). We reliably quantified 146 blood
metabolites and 79 metabolite ratios. Figure 1 shows the
number of participants remaining after quality control and
after assessment of the completeness of phenotype in-
formation in the different analyses performed.
Single-metabolite logistic regression
To identify metabolite biomarkers potentially asso-
ciated with future pancreatic cancer diagnosis, we
performed a separate logistic regression for each me-
tabolite measured. In our primary model, we adjusted for
the following covariates: sex, age, BMI, smoking status,
T2DM status, fasting status, and cohort. The results of
our topmetabolites are presented in Table 2. Full data are
provided in an online repository (32). Two metabolites
demonstrated lower blood levels in cases than in controls
and nominal significance: glutamine (P 5 0.012) and
histidine (P 5 0.011). They were not significant after
adjustment for multiple testing (Westfall–Young family-
wise error rate adjusted P value of 0.43 for both me-
tabolites). To estimate the clinical relevance of our
findings, the ORs for being diagnosed with pancreatic
cancer within the follow-up time was calculated for an
individual with metabolite levels of 1 SD below the
mean: these ORs amounted to 1.42 and 1.45 for glu-
tamine and histidine, respectively (see footnote to
Table 2). A closer inspection of the levels of glutamine
and histidine revealed that the differences were con-
sistently observed across cohorts (Fig. 2A and 2E),
except for glutamine in RS and histidine in FR. Glu-
tamine levels were lower in both nondiabetics and pa-
tients with diabetes, whereas lower histidine levels were
mainly observed in patients with pancreatic cancer who
were also diagnosed with T2DM (Fig. 2B). Histidine
levels were lower in individuals who developed pan-
creatic cancer within 2 years after blood sampling,
whereas glutamine levels were decreased longer before
diagnosis (Fig. 2C and 2G). Histidine levels were lower
in both fasting and nonfasting individuals (Fig. 2H),
whereas the effect of fasting status on glutamine levels is
difficult to ascertain given the differences between co-
horts in fasting status (Fig. 2D). The branched chain
amino acids, leucine, valine, and isoleucine, reported
earlier by Mayers et al. (11), were not different between
cases and controls (unadjusted P values of 0.75, 0.94,
and 0.61, respectively).Ta
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The results above were recapitulated in a minimally
adjusted model, only corrected for sex and age (32).
Glutamine and histidine were still among the top hits,
with P values of 0.0063 and 0.00045 (not adjusted for
multiple testing), respectively.
To further address potential cohort differences, we
performed a meta-analysis on the b coefficients from the
logistic regression models that were applied per cohort.
The results are summarized in Table 3 and provided in
full in an online repository (32). The results from the
Table 2. Top Hits From Logistic Regression Analysis
Metabolitea Estimateb SE z Value P Value Adjusted P Value
Histidine 20.188 0.074 22.529 0.011 0.4274
Glutamine 20.175 0.069 22.525 0.012 0.4274
DHA.FA 0.195 0.081 2.393 0.017 0.5214
FAw3.FA 0.170 0.075 2.272 0.023 0.6203
M.HDL.P 20.151 0.072 22.085 0.037 0.7646
M.HDL.L 20.149 0.072 22.076 0.038 0.7695
DHA 0.153 0.075 2.029 0.043 0.7975
M.HDL.PL 20.145 0.072 22.020 0.043 0.8016
M.HDL.C 20.139 0.071 21.941 0.052 0.8513
M.HDL.CE 20.138 0.072 21.929 0.054 0.8589
M.HDL.PL 0.141 0.074 1.898 0.058 0.8756
Abbreviations: DHA, docosahexaenoic acid; HDL, high-density lipoprotein; DHA.FA, ratio of docosahexaenoic acid to all fatty acids; FAw3.FA, ratio of v-3
fatty acids to total acids; M.HDL.P, concentration of medium HDL particles; M.HDL.PL: phospholipids in medium-sized HDL particles.
aLogistic regression with single metabolite measure, sex, age, BMI, smoking status, T2DM status, fasting status, and cohort as covariates.
bThe estimates are the fitted b coefficients from the logistic regression model. As the input metabolite data were scaled, the estimates can be interpreted
as follows: the OR for developing pancreatic cancer in a case with a typical lowmetabolite score of 1 SD below the average z score (521) would amount
to 1.22 for b of 20.1 and 1.49 for b of 20.2. The z value mentioned in the table is the test statistic from the logistic regression models.
Figure 2. Concentrations (logarithmic scale) of (A–D) glutamine and (E–H) histidine in the blood circulation in controls and cases, that is, those
individuals who developed pancreatic cancer within a time window after blood sampling. (A and E) Distribution of the concentrations of controls
(light blue) and cases (dark blue) in the different cohorts analyzed (EGCUT, FR, HUNT2, HUNT3, RS). (B and F) Distribution of concentrations in
nondiabetics (light blue) and individuals diagnosed with T2DM (dark blue). (C and G) Distribution of concentrations in controls and cases
sampled within 2 y before diagnosis, between 2 and 5 y before diagnosis, and .5 y before diagnosis. (D and H) Distribution of concentrations
in nonfasting individuals (light blue), individuals who had a meal between 4 and 8 h before blood draw (dark blue), and fasting individuals
(green, last meal was .8 h before blood draw). Box plots reflect the distribution of the concentrations in individual samples, including the
middle quartiles (25th to 75th percentile of the data points are in the boxes); the horizontal band; the median value; the lower whiskers
representing the data points up to 1.5 3 the interquartile range (IQR) below the 25th percentile; the upper whiskers representing the data
points up to 1.5 3 IQR above the 75th percentile; the data points outside these ranges plotted as individual data points.
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meta-analysis corroborated our findings on the pooled
data, with lower glutamine levels seen for all cohorts
(unadjusted P value of 0.0040), but most prominently in
HUNT3 (Fig. 3A), and lower histidine levels mostly in
HUNT3 and EGCUT (unadjusted P value of 0.0022)
(Fig. 3B, with similar trends in other cohorts and evi-
dence for significant heterogeneity between cohorts).
The mean ORs for an increase of 1 SD in glutamine or
Table 3. Top Hits From Meta-Analysis
Metabolitea b CI Unadjusted P Value P Value I2 (%)
Glutamine 20.19538 20.33:20.06 0.004 0.9037087 0
DHA.FA 0.17259 0.04:0.3 0.0083 1 0
M.HDL.PL 20.17905 20.32:20.04 0.0103 1 0
M.HDL.P 20.17856 20.32:20.04 0.0104 1 0
M.HDL.L 20.17732 20.31:20.04 0.0104 1 0
FAw3.FA 0.16222 0.03:0.29 0.0126 1 0
Histidine 20.25164 20.46:20.05 0.0156 1 0.53
M.HDL.FC 20.15636 20.29:20.02 0.0251 1 0
M.HDL.C 20.15174 20.29:20.02 0.0267 1 0
M.HDL.CE 20.14723 20.28:20.01 0.0306 1 0
DHA 0.13222 0:0.26 0.0438 1 0
Abbreviations: DHA, docosahexaenoic acid; DHA.FA, ratio of docosahexaenoic acid to total fatty acids; FAw3.FA, ratio of v-3 fatty acids to total acids;
HDL, high-density lipoprotein; M.HDL.C, total cholesterol in medium-sized HDL particles; M.HDL.CE, cholesterol esters in medium-sized HDL particles;
M.HDL.FC, free cholesterol in medium-sized HDL particles; M.HDL.L, total lipids in medium-sized HDL particles; M.HDL.P, concentration of medium-sized
HDL particles; M.HDL.PL, phospholipids in medium-sized HDL particles.
aMeta-analysis across the five cohorts of logistic regression results with single metabolite measure, sex, age BMI, smoking status, T2DM status, and
fasting status as covariates.b is effect size and can be interpreted as detailed in footnote b to Table 2. P value is Bonferroni–Holm-adjusted P value. I2 is the
statistic used for heterogeneity between cohorts.
Figure 3. Forest plots from random effects meta-analysis across different cohorts for (A) glutamine and (B) histidine. The meta-analysis was
performed on the b coefficients and SD from the logistic regressions run for each cohort separately. In the logistic regression, pancreatic cancer
status was modeled as a function of log-transformed and standardized metabolite concentration, sex, age, BMI, smoking status, T2DM, and
fasting status. Shown are the estimated effect size, the SE on this estimate, the estimated OR and the CI on this ratio, the weight of the
individual cohort on the calculation of the final estimate, the heterogeneity measure (modeling differences between cohorts), and the unadjusted
and Bonferroni–Holm-corrected P values for the respective metabolites.
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histidine levels were 0.82 and 0.78 (or 1.22 and 1.28
for a decrease of 1 SD), respectively. The meta-analysis
provided some evidence for the involvement of v-3 fatty
acids (including docosahexaenoic acid and high-density
lipoproteins).
To provide a better understanding of the lower
glutamine or histidine levels, we stratified the cohorts in
quintiles based on the glutamine or histidine levels in
controls. Individuals within the lowest 20% of gluta-
mine levels ran a 1.5-fold elevated risk of pancreatic
cancer, and individuals within the lowest 20% of his-
tidine levels ran a 2.2-fold elevated risk of pancreatic
cancer (Table 4).
LASSO regression
LASSO regression was used to evaluate the additional
predictive value of metabolomics biomarkers over clinical
predictors. The performance of a reference (null) model, in
which only the clinical covariates were used for prediction,
was compared with an alternative model, in which me-
tabolites selected by the LASSO regression were added to
the model. The cases were stratified according to the time
until diagnosis (up to 2 years, up to 5 years, and all cases
without temporal constraint). In themodel with cases up to
2 years until diagnosis, the LASSO regression selected
medium very low-density lipoprotein (VLDL), total un-
saturated fatty acids, and saturated fatty acids to be in-
cluded in the model (Table 5), but it did not affect the
performance on the 30% of the data that were unseen
during the selection of the metabolites. In the model with
cases up to 5 years until diagnosis, the LASSO regression
model selected small VLDL and glutamine (consistent with
the prominent decrease of glutamine levels in cases between
2 and 5 years before diagnosis) (Table 5). The performance
of the alternative model increased slightly for both the
training (AUC of 0.72 vs 0.71 for the null model, Fig. 4A)
Table 4. ORs for Developing Pancreatic Cancer in Different Glutamine and Histidine Strata
Based on Control Data Controls, n Cases, n OR 5% CI 95% CI P Value
Glutamine
0% 0.269 180 94 1 — —
20% 0.4538 176 66 0.72 0.49 1.05 0.0852
40% 0.487 177 62 0.67 0.46 0.98 0.0404
60% 0.5157 176 71 0.77 0.53 1.12 0.1734
80% 0.55358 178 62 0.66 0.46 0.98 0.0376
Histidine
0% 0.03927 178 110 1 — —
20% 0.060498 177 71 0.65 0.45 0.93 0.0199
40% 0.064778 177 58 0.53 0.36 0.78 0.0011
60% 0.068174 177 66 0.6 0.42 0.87 0.0073
80% 0.072638 178 51 0.46 0.31 0.69 0.0001
Table 5. Variables Selected by the LASSO Regression
Cohort Time Condition l Selected Variables P Value Significance
Full data 2 y 6.06 M.VLDL.FC_, UnSat, SFA.FA 0.175
Full data 5 y 28.3 S.VLDL.FC_, Gln 0.0114 P , 0.05
Full data Max(t) 2.02 XL.VLDL.TG, XL.HDL.TG,M.HDL.PL, XXL.VLDL.PL_.,
XXL.VLDL.CE_, L.VLDL.PL_, L.VLDL.FC_,
M.LDL.TG_, XL.HDL.CE_, XL.HDL.FC_,
L.HDL.FC_, FreeC, SMs, LA, DHA.FA, LA.FA, Glc,
Cit, Ala, Gln, His, Val, Phe, AcAce, bOHBut, Crea
0.102
The results of the cross-validated LASSO-penalized logistic regression for the full dataset are shown. For each regression the penalty parameter (l) and the
selected covariates (separated by commas) are given. For every model where metabolites were selected, the significance of the presence of all of the
selected metabolites in the model, compared with the model without presence of metabolites, is tested in a global test, and its P value is given here. Note
that the P value is only for the metabolites, not for the clinical covariates.
Abbreviations: AcAce, acetoacetate; Ala, alanine; bOHBut, 3-hydroxybutyrate; Cit, citrate; Crea, creatinine; DHA.FA, ratio of docosahexaenoic acid to
total fatty acids; FreeC, free cholesterol; Glc, glucose; Gln, glutamine; His, histidine; LA, linoleic acid; LA.FA, ratio of linoleic acid to total fatty acids;
L.HDL.FC_, free cholesterol to total lipids ratio in large HDLs; L.VLDL.FC_, free cholesterol to total lipids ratio in large VLDLs; L.VLDL.PL_, phospholipids to
total lipids ratio in large VLDLs; M.HDL.PL, phospholipids in medium-sized HDLs; M.LDL.TG_, triglycerides to total lipids ratio in medium LDLs; M.VLDL.FC_,
free cholesterol to total lipids ratio in medium VLDLs; Phe, phenylalanine; SFA.FA, ratio of saturated fatty acids to total fatty acids; SM, sphingomyelin;
S.VLDL.FC_, free cholesterol to total lipids ratio in small VLDLs; UnSat, estimated degree of unsaturation; Val, valine; XL.HDL.CE_, cholesterol ester to total
lipids ratio in very large HDLs; XL.HDL.FC_, free cholesterol to total lipids ratio in very large HDLs; XL.HDL.TG, triglycerides in very large HDLs; XXL.VLDL.CE_,
cholesterol esters to total lipids ratio in chylomicrons and extremely large VLDLs; XL.VLDL.TG, triglycerides in extra-large VLDL particles; XXL.VLDL.PL_,
phospholipids to total lipids ratio in chylomicrons and extremely large VLDLs.
1738 Fest et al Metabolomic Biomarkers in Early Pancreatic Cancer Endocrinology, July 2019, 160(7):1731–1742
D
ow
nloaded from
 https://academ
ic.oup.com
/endo/article-abstract/160/7/1731/5497119 by Erasm
us U
niversiteit R
otterdam
 user on 21 August 2019
and the validation set (AUC of 0.64 vs 0.62 for the null
model, Fig. 4B). In the model with all cases included, more
metabolites were selected (Table 5), but the performance of
the model including the metabolites on both training and
validation set (AUC of 0.68 and 0.62, respectively) was
worse than for the model with cases up to 5 years.
Discussion
Pancreatic cancer is usually diagnosed in an advanced
stage of the disease, resulting in a poor prognosis. Most
pancreatic cancer biomarker
studies executed until today (9,
10, 13–16) collected samples at the
time of diagnosis or even later,
and therefore have limited clini-
cal utility. However, they may
provide insight in the pathophysi-
ology of the disease. The setup of
our study allowed for the identifi-
cation of biomarkers in indivi-
duals who were not yet diagnosed
with pancreatic cancer, and made
efficient use of the large-scale bio-
banking infrastructure in Europe
(BBMRI-LPC program).
We identified two potential
biomarkers, glutamine and histi-
dine, while noting that the differ-
ences between cases and controls
were small and did not survive
stringent multiple testing pro-
cedures, and that the clinical utility
of these biomarkers is currently
low. The increased risk of pan-
creatic cancer associated with low
levels of glutamine and histidine
was calculated to be only 1.5-fold
to 2.2-fold and does not add much
in terms of predictive potential to
well-known risk factors for pan-
creatic cancer such as age, smok-
ing, and T2DM. However, also
earlier studies provided evidence
for alterations in glutamine and
histidine in pancreatic cancer (10,
15, 16, 33), suggesting that these
may indeed be associated with pan-
creatic cancer–associated changes
in metabolism. In the largest study
by Fukutake et al. (15) (N 5 360
vs 8372), histidine was found
particularly low in patients with
resectable disease stage 0-IIB. This group of patients
in a relatively early state of the disease is likely most
similar to our group of individuals who were diagnosed
in ,2 years after blood sampling and had the lowest
histidine levels of all cases. Also, in other cancer-related
studies, negative correlations between histidine levels and
cancer incidence and/or cancer-associated mortality were
observed (34–36). Remarkably, a recent report demon-
strated also lower efficacy of cancer treatment in
individuals with low histidine levels, and suggested
histidine supplementation to enhance the efficacy of
Figure 4. Receiver operator curves for classification of pancreatic cancer cases (sampled up to 5 y
before diagnosis) and controls for (A) training set (70% of all individuals) and (B) performance
testing set (30% of all individuals unseen during the variable selection). In red, the null model is
shown in which only the clinical covariates (sex, age, BMI, smoking status, T2DM, and fasting
status) were included in the regression. In blue, the alternative model is shown where the
metabolites selected by the LASSO regression were included in addition to the clinical covariates.
The AUCs are indicated, as well as the specificity (1 2 false-positive rate) at 70% sensitivity.
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methotrexate treatment in leukemia (37). In a study by
Roux et al. (33), human pancreatic ductal adenocarci-
noma (PDAC) cell lines displayed higher glutamine
uptake and metabolism than did non-PDAC cancer cell
lines, in line with our study.Moreover, mouse models in
which human PDAC cells were injected into the pan-
creas demonstrated lower levels of circulating gluta-
mine than control animals, which could not be
explained by inflammation of the pancreas nor by the
development of T2DM (33). This makes it unlikely
that the identification of glutamine and histidine in
our study is due to pancreatitis, often associated with
pancreatic cancer, but we can only formally exclude this
possibility by including a cohort of patients with
chronic inflammation of the pancreas.
One of the reasons why changes in metabolites such
as glutamine and histidine are difficult to detect is that
the concentrations of these metabolites are relatively
high, and that local events, such as a pancreatic tumor,
contribute only little to the overall pool of these me-
tabolites. Other metabolites may be more specific to
the metabolism in the pancreas and may show more
prominent changes. These types of metabolites require
broader metabolomic screening than the Nightingale
platform provides. Although having superior robustness
and throughput and low cost, the range of metabolites
measured on the Nightingale platform is limited to amino
acids, other polar metabolites, and a large range of lipid
and lipoprotein classes. Our study calls for the use of
complementary biomarker platforms on these samples,
and suggests to limit the sampling to within 5 years
before diagnosis and not beyond.
Our study was not able to replicate the findings from
the single study with a design and sample size compa-
rable to ours (11). This study identified the branched-
chain amino acids valine, leucine, and isoleucine as
potential prognostic biomarkers for pancreatic cancer.
We did not find any difference between cases and con-
trols for these amino acids, nor were our top metabolites
identified in this earlier study. This may be a reflection of
the limited power of both studies for the discovery of
small changes observed for these metabolites. However,
we did not even observe trends in the same directions.
Differences in the measurement platforms (1H-NMR vs
liquid chromatography followed by mass spectrometry)
may play a role, but the different amino acids can robustly
be measured by both. It is equally plausible that the dif-
ferences are due to differences in the studied populations
or confounding factors, which were not or were in-
completely corrected for in the statistical model, such as
nutrition.
In conclusion, our study lends initial support to the
existence of metabolic alterations in early pancreatic
cancer development, highlighting glutamine and histi-
dine as metabolites of interest, but also underscores the
challenges to find robust, prognostic biomarkers for
rare disorders. To address this, larger studies are
needed, including more metabolites with lower concen-
trations and/or integrated studies at multiple “omics”
levels.
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